Panchia, Ravindre

Antiretroviral therapy for the prevention of HIV-1 transmission.

Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2016) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV Research and Treatment

Cited by 1,700

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 523

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

Sanne, I., Orrell, C., Fox, M. P., Conradie, F., Ive, P., Zeinecker, J., Cornell, M., Heiberg, C., Ingram, C., Panchia, R., et al. (2010) · The Lancet

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 248

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

Delany-Moretlwe, S., Lombard, C., Baron, D., Bekker, L.-G., Nkala, B., Ahmed, K., Sebe, M., Brumskine, W., Nchabeleng, M., Palanee-Philips, T., et al. (2018) · The Lancet Infectious Diseases

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 95